Repligen Corp. (RGEN)

NASDAQ

$175.58

$+3.03

(+1.76%)

After-Hours

Repligen Corp. (RGEN) Live Price Chart

Last updated: ⁦2026-10-13 21:25:00⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Repligen Corp. (RGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $175.58, with a market capitalisation of $11.04B and a P/E ratio of 263.67. Over the past 52 weeks, its price has ranged from $100.99 to $198.87. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$11.04B
Open	$172.51
Day's High	$327.32
Day's Low	$1.22
Previous Close	$172.51
Volume	994.14K
Average Volume	1.20M
P/E Ratio	263.67
52-Week High	$198.87
52-Week Low	$100.99
Dividend Yield	--
Earnings Date	--

Repligen Corp. (RGEN) After-Hours Stock Price

Repligen Corp. (RGEN) is trading at $175.58 in after-hours trading as of 2026-10-13 20:45:00, up 1.78% ($3.07) from the regular-session close of $172.51.

After-hours trading shows how investors are pricing RGEN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.

Repligen Corp. (RGEN) 7-Day Stock Price Change

Over the past seven days, Repligen Corp. (RGEN) moved from $181.70 to $175.58, representing a decline of 3.37% ($6.12).

The stock traded between $157.44 and $194.36 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.

The average daily volume was 1.55 million shares, up versus the previous seven-day period, indicating higher trading activity.

RGEN 52-Week Price Position

Position in Range: 76.2%

52W Low$100.99

52W High$198.87

RGEN is currently trading at $175.58, placing it 76.2% of the way from its 52-week low of $100.99 to its 52-week high of $198.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Repligen Corp. (RGEN)?

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Repligen Corp. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	2000
Exchange	NASDAQ
Company Website	https://www.repligen.com

How to Buy Repligen Corp. (RGEN) Stock on MEXC

Eligible investors can buy real shares of Repligen Corp. (RGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for RGEN and Place Your Order

Open the RealStocks trading page and search for RGEN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Repligen Corp. (RGEN) stock price today?

Repligen Corp. (RGEN) is currently trading at $ 175.58, up 1.78% ($3.07) from the previous close of $ 172.51. Intraday prices update in real time during regular trading hours.

2.Is RGEN stock going up or down today?

As of 2026-10-13 20:45:00, RGEN is trading at $ 175.58, up 1.78% ($3.07) from its previous close of $ 172.51. The stock has traded between $ 1.22 and $ 327.32 during today’s regular session. Past price movements do not guarantee future results.

3.What is RGEN pre-market price?

As of 2026-10-13 20:45:00, RGEN is trading at $ 172.01 in pre-market trading, down 0.29% ($0.50) from the previous close of $ 172.51. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is RGEN after-hours price?

As of 2026-10-13 20:45:00, RGEN is trading at $ 175.58 in after-hours trading, up 1.78% ($3.07) from the regular-session close of $ 172.51. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is RGEN stock trading now?

RGEN trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does RGEN sit relative to its 52-week high and low?

Over the past 52 weeks, RGEN has traded between a low of $ 100.99 and a high of $ 198.87. At $ 175.58, the stock is positioned 76.2% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Repligen Corp. in?

Repligen Corp. (RGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Repligen Corp.'s market capitalisation and where is it listed?

Repligen Corp. is listed on the NASDAQ exchange with a market capitalisation of $ 11.04B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is RGEN valued in terms of P/E ratio and EPS?

RGEN trades at a P/E ratio of 263.67, based on trailing-twelve-month EPS of $ 0.65. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Repligen Corp. pay a dividend?

Repligen Corp. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.